TrialCancer science2014

Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma.

Masatoshi Eto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.